Delivery of whole tumor lysate into dendritic cells for cancer vaccination
/in Dendritic Cells, Hypernephroma, International Publications, NSCLC /von 2008-01-01 / Methods Mol. Biol. 2008;423:139-53Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma
/in Hypernephroma, International Publications /von 2007-10-03 / Clin. Immunol. 2007 Dec;125(3):257-67Apoptic renal carcinoma cells are better inducers of cross-presenting activity than their primary necrotic counterpart
/in Hypernephroma, International Publications /von 2007-10-01 / Int J Immunopathol Pharmacol 2007 Oct-Dec;20(4):707-17Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
/in Hypernephroma, International Publications /von 2007-10-01 / J. Immunother. 2007 Oct;30(7):749-61Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine
/in Hypernephroma, International Publications /von 2007-09-01 / J. Immunol. 2007 Sep;179(5):2860-9Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study
/in Hypernephroma, International Publications /von 2007-09-01 / Oncol. Rep. 2007 Sep;18(3):665-71Dendritic cell vaccination
/in Breast Cancer, Colorectal Cancer, Hypernephroma, International Publications, Malignant Melanoma, Prostate Cancer /von 2007-08-01 / Expert Rev Vaccines 2007 Aug;6(4):617-33Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression
/in Hypernephroma, International Publications /von 2007-04-20 / Clin. Immunol. 2007 Jun;123(3):298-310DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors
/in Dendritic Cells, Hypernephroma, International Publications /von 2007-04-19 / Cancer Immunol. Immunother. 2007 Nov;56(11):1817-29IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de